Opportunity Information: Apply for PA 09 237
Apply for PA 09 237
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Jul 22, 2009 and posted on Jul 22, 2009.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses State governments City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts County governments Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Special district governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21) funding opportunity (PA-09-237) was issued by the National Institute on Drug Abuse (NIDA) within the National Institutes of Health (NIH) to support exploratory, early-stage research focused on how drug use contributes to the HIV/AIDS epidemic among vulnerable populations in the United States. The central idea behind the announcement is that HIV/AIDS has placed a deeply disproportionate burden on certain groups, particularly racial and ethnic minorities, men who have sex with men, and youth, and that drug use (including both injection and non-injection drug use) can increase risk and worsen outcomes through multiple pathways. The program emphasizes that reducing new infections and improving the health and well-being of people living with HIV requires a clearer, evidence-based understanding of the biological, behavioral, psychosocial, environmental, and institutional factors that shape vulnerability and drive transmission within these communities.
The FOA highlights several major research directions. One priority is studying how drug abuse contributes to HIV acquisition and transmission, recognizing that risk is not limited to injection practices alone and can also be influenced by substance-related sexual risk behaviors, impaired judgment, co-occurring mental health conditions, and patterns of partnership and exposure. A second focus is examining HIV disease progression and health outcomes in the context of substance use, which can affect immune functioning, comorbidities, medication adherence, access to care, and long-term clinical outcomes. A third area encourages the development, refinement, and testing of prevention and treatment interventions that can reduce HIV transmission and improve outcomes for people living with HIV who also use drugs; this can include behavioral interventions, service delivery innovations, and strategies that integrate HIV prevention or care with substance use treatment. A fourth emphasis is on organizational, structural, and community-level influences, including the role of social, sexual, and drug-using networks, and how institutional environments and community conditions can amplify or reduce HIV risk and shape access to effective services.
This opportunity uses the NIH R21 mechanism, which is typically intended for exploratory or developmental projects that can generate preliminary data, test novel concepts, or establish feasibility for larger studies. The FOA is described as running in parallel with a companion announcement of identical scientific scope that uses the R01 mechanism (PA-09-236), which generally supports larger, more mature research projects. Funding decisions under PA-09-237 were contingent on the availability of funds and the receipt of a sufficient number of scientifically meritorious applications, rather than a guaranteed number of awards.
In terms of administrative details, the program was categorized as discretionary grant funding with a health and education-related activity category and associated with CFDA number 93.279 (Drug Abuse and Addiction Research Programs). There was no cost sharing or matching requirement. The opportunity was posted on July 22, 2009, and ultimately closed on September 7, 2012, with an archive date of October 8, 2012.
Eligibility was broad and included many types of applicants across public and private sectors. Eligible applicants listed in the notice included small businesses; for-profit organizations (including those other than small businesses); nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities); public and private institutions of higher education; state, county, city or township, special district governments, and independent school districts; public housing authorities/Indian housing authorities; and Native American tribal governments and tribal organizations (including federally recognized tribes and other tribal entities). The eligibility section also explicitly referenced additional eligible groups such as faith-based and community-based organizations, Alaska Native and Native Hawaiian Serving Institutions, Hispanic Serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), regional organizations, eligible federal agencies, and U.S. territories or possessions. Overall, the structure of eligibility reflects an intent to attract proposals from academic researchers, community and service organizations, healthcare and public health systems, and other institutions positioned to study HIV and substance use where they intersect in real-world settings.
The full announcement was made available through the NIH Grants Guide, and the notice provided webmaster contacts for technical issues accessing the posting.
FAQs: HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21) (PA-09-237)
What is this funding opportunity?
This is a National Institutes of Health (NIH) funding opportunity announcement (FOA) issued by the National Institute on Drug Abuse (NIDA) titled "The HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21)" with FOA number PA-09-237.
What is the main purpose of PA-09-237?
The FOA supports exploratory, early-stage research focused on how drug use contributes to the HIV/AIDS epidemic among vulnerable populations in the United States, with the goal of strengthening evidence about the factors that drive vulnerability, transmission, and health outcomes.
Which populations does the FOA describe as disproportionately affected by HIV/AIDS?
The announcement highlights that HIV/AIDS has placed a deeply disproportionate burden on certain groups, particularly racial and ethnic minorities, men who have sex with men, and youth.
How does the FOA define the role of drug use in HIV risk and outcomes?
The FOA frames drug use (including both injection and non-injection drug use) as increasing risk and worsening outcomes through multiple pathways, including behavioral and contextual mechanisms as well as biological and institutional influences.
Is the research focus limited to injection drug use?
No. The FOA explicitly recognizes that HIV acquisition and transmission risk is not limited to injection practices alone and can also be influenced by non-injection substance use and related factors such as substance-related sexual risk behaviors and impaired judgment.
What types of factors does the FOA encourage researchers to examine?
The FOA emphasizes the need for an evidence-based understanding of biological, behavioral, psychosocial, environmental, and institutional factors that shape vulnerability and drive transmission in affected communities.
What are the major research directions highlighted in the FOA?
The FOA highlights four broad research directions: (1) how drug abuse contributes to HIV acquisition and transmission; (2) HIV disease progression and health outcomes in the context of substance use; (3) development, refinement, and testing of prevention and treatment interventions that reduce transmission and improve outcomes for people living with HIV who use drugs; and (4) organizational, structural, and community-level influences on risk and access to effective services.
What does the FOA say about studying HIV acquisition and transmission?
One priority area is research on how drug abuse contributes to HIV acquisition and transmission, including pathways involving substance-related sexual risk behaviors, impaired judgment, co-occurring mental health conditions, and patterns of partnership and exposure.
What does the FOA emphasize about HIV disease progression and clinical outcomes?
A second focus area is examining HIV disease progression and health outcomes in the context of substance use, noting that substance use can affect immune functioning, comorbidities, medication adherence, access to care, and long-term clinical outcomes.
What kinds of interventions does the FOA encourage?
The FOA encourages the development, refinement, and testing of prevention and treatment interventions that can reduce HIV transmission and improve outcomes for people living with HIV who also use drugs. Examples mentioned include behavioral interventions, service delivery innovations, and strategies that integrate HIV prevention or care with substance use treatment.
Does the FOA include structural or community-level research?
Yes. A fourth emphasis is on organizational, structural, and community-level influences, including social, sexual, and drug-using networks and how institutional environments and community conditions can increase or reduce HIV risk and shape access to effective services.
What funding mechanism is used for this FOA?
This opportunity uses the NIH R21 mechanism, which is typically intended for exploratory or developmental projects that can generate preliminary data, test novel concepts, or establish feasibility for larger studies.
Is there a related FOA for larger projects?
Yes. The FOA is described as running in parallel with a companion announcement of identical scientific scope using the NIH R01 mechanism (PA-09-236), which generally supports larger, more mature research projects.
Are awards guaranteed under PA-09-237?
No. Funding decisions were contingent on the availability of funds and the receipt of a sufficient number of scientifically meritorious applications, rather than a guaranteed number of awards.
What type of grant program category is this?
The program was categorized as discretionary grant funding, with a health and education-related activity category.
What is the CFDA number associated with this opportunity?
The FOA is associated with CFDA number 93.279, Drug Abuse and Addiction Research Programs.
Is cost sharing or matching required?
No. The FOA states there was no cost sharing or matching requirement.
When was this opportunity posted?
The opportunity was posted on July 22, 2009.
When did PA-09-237 close?
The FOA ultimately closed on September 7, 2012, with an archive date of October 8, 2012.
Who was eligible to apply?
Eligibility was broad and included applicants across public and private sectors, including small businesses; for-profit organizations (including those other than small businesses); nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities); public and private institutions of higher education; and multiple types of government entities.
Which government entities were listed as eligible applicants?
Eligible government applicants included state governments; county, city or township governments; special district governments; independent school districts; public housing authorities/Indian housing authorities; Native American tribal governments; and tribal organizations (including federally recognized tribes and other tribal entities).
Did the FOA explicitly include faith-based or community-based organizations?
Yes. The eligibility section explicitly referenced additional eligible groups such as faith-based and community-based organizations.
Did the FOA encourage applications from minority-serving institutions?
The eligibility language explicitly referenced Alaska Native and Native Hawaiian Serving Institutions, Hispanic Serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Were U.S. territories included in eligibility?
Yes. The eligibility section explicitly referenced U.S. territories or possessions.
Where was the full announcement made available?
The full announcement was made available through the NIH Grants Guide.
What support was mentioned for technical issues accessing the posting?
The notice provided webmaster contacts for technical issues accessing the posting.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21)
Previous opportunity: HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 237
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 237) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21) Apply for PA 09 238 Funding Number: PA 09 238 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 09 239 Funding Number: PAR 09 239 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Early Detection Research Network Clinical Validation Centers (U01) Apply for RFA CA 09 018 Funding Number: RFA CA 09 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $600,000 |
| The Early Detection Research Network Biomarker Reference Laboratories (U24) Apply for RFA CA 09 019 Funding Number: RFA CA 09 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Detection Research Network Data Management and Coordinating Center and Statistics and Biomarker Resource Center (U24) Apply for RFA CA 09 020 Funding Number: RFA CA 09 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Support for Human Specimen Banking in NCI Supported Clinical Trials Cooperative Group Banks (CGB) (U24) Apply for RFA CA 09 504 Funding Number: RFA CA 09 504 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Substance Use and Abuse among U.S. Military Personnel, Veterans and their Families (R01) Apply for RFA DA 10 001 Funding Number: RFA DA 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Substance Use and Abuse among U.S. Military Personnel, Veterans and their Families (R21) Apply for RFA DA 10 002 Funding Number: RFA DA 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| NIMH Career Transition Award for Intramural Investigators (K22) Apply for PAR 09 246 Funding Number: PAR 09 246 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovations in Biomedical Computational Science and Technology Initiative (SBIR R43/R44) Apply for PAR 09 220 Funding Number: PAR 09 220 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovations in Biomedical Computational Science and Technology Initiative (STTR R41/R42) Apply for PAR 09 221 Funding Number: PAR 09 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Optimization of Small Molecule Probes for the Nervous System (R21) Apply for PAR 09 251 Funding Number: PAR 09 251 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Image guided Drug Delivery in Cancer (R01) Apply for PA 09 253 Funding Number: PA 09 253 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Biology of Estrogen Receptor Negative Breast Cancer in Various Racial and Ethnic Groups (U01) Apply for RFA CA 09 026 Funding Number: RFA CA 09 026 Agency: National Institutes of Health Category: Education Health Funding Amount: $667,000 |
| Nutrition and Physical Activity Research to Promote Cardiovascular and Pulmonary Health (R01) Apply for PA 09 243 Funding Number: PA 09 243 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Nutrition and Physical Activity Research to Promote Cardiovascular and Pulmonary Health (R21) Apply for PA 09 244 Funding Number: PA 09 244 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Optimization of Small Molecule Probes for the Nervous System (STTR R41) Apply for PAR 09 259 Funding Number: PAR 09 259 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Optimization of Small Molecule Probes for the Nervous System (SBIR R43) Apply for PAR 09 260 Funding Number: PAR 09 260 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 09 019 Funding Number: RFA RM 09 019 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition for Research Centers in Minority Institutions Infrastructure for Clinical and Translational Research (RCTR) U54 Apply for PAR 09 261 Funding Number: PAR 09 261 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 237", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.